Rohto Pharmaceutical Co.,Ltd.
4527.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | ¥468 | ¥513 | ¥658 |
| - Cash | ¥74 | ¥76 | ¥77 | ¥62 |
| + Debt | ¥27 | ¥49 | ¥50 | ¥39 |
| Enterprise Value | – | ¥441 | ¥486 | ¥635 |
| Revenue | ¥82 | ¥82 | ¥83 | ¥87 |
| % Growth | 0.4% | -0.9% | -4.7% | – |
| Gross Profit | ¥45 | ¥46 | ¥45 | ¥50 |
| % Margin | 54.5% | 55.9% | 54.7% | 58.2% |
| EBITDA | ¥13 | ¥15 | ¥13 | ¥17 |
| % Margin | 15.5% | 18.2% | 15.2% | 19% |
| Net Income | ¥6 | ¥12 | ¥6 | ¥12 |
| % Margin | 7.2% | 14.4% | 7.5% | 13.7% |
| EPS Diluted | 25.01 | 51.39 | 27.04 | 51.95 |
| % Growth | -51.3% | 90.1% | -47.9% | – |
| Operating Cash Flow | – | ¥0 | ¥0 | ¥0 |
| Capital Expenditures | – | ¥0 | ¥0 | ¥0 |
| Free Cash Flow | – | ¥0 | ¥0 | ¥0 |